TNF and inflammatory bowel disease: These antibodies can modulate immune responses, inhibit cell signaling pathways, and neutralize pathogenic targets, making them valuable tools in precision medicine and targeted therapy.[7] Adalimumab, a monoclonal antibody targeting tumor necrosis factor alpha (TNF‐α), has demonstrated remarkable efficacy in the management of autoimmune disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.